Borato-1, 2-diaminocyclohexane platinum (II), a novel anti-tumor drug

Biochemical and Biophysical Research Communications

Volumn 270, Issue 2, 2000, Pages 383-386

  Dibas, Adnan ^a   Howard, Jeremy ^a   Anwar, Shehab ^a   Stewart, David ^a   Khan, Amanullah ^a  

^a University Hospital St Paul Medical Center   (United States)

Author keywords

Cisplatin; DNA synthesis; L1210; Leukemia; Platinum

Indexed keywords

ANTINEOPLASTIC AGENT; BARIUM DERIVATIVE; BORATO 1,2 DIAMINOCYCLOHEXANE PLATINUM; CISPLATIN; CYCLOHEXANE DERIVATIVE; PLATINUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA L 1210; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; MURINAE;

EID: 0034643297     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2440     Document Type: Article

References (15)

1. Rosenberg B., VanCamp L., Trosko J. E., Mansour V. H. Platinum compounds: A new class of potent antitumor agents. Nature. 222:1969;385-386.
2. 2]. Science. 218:1982;1075-1082.
3. Rosenberg B., VanCamp L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 30:1970;1799-1802.
4. Rosenberg B. Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chemother. Rep. 59:1975;589-598.
5. Malinge J. M., Giraud-Panis M. J., Leng M. Interstrand cross-links of cisplatin induce striking distortion. J. Inorg. Biochem. 77:1999;23-29.
6. Johnson, S. W., Swiggard, P. A., Handel, L. M., Brennan, J. M., Godwin, A. K., Ozols, R. F., and Hamilton, T. C.Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res.15, 5911-5916.
7. Doz F., Berens M. E., Dougherty D. V., Rosenblum M. L. Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J. Neurooncol. 11:1991;27-35.
8. Poirier M. C., Reed E., Litterst C. L., Katz D., Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res. 52:1992;149-153.
9. Reed E., Yuspa S. H., Zwelling L. A., Ozols R. F., Poirier M. C. Quantitation of cis-diaminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving chemotherapy. J. Clin. Invest. 77:1986;545-550.
10. Wolfgang G. H., Dominick M. A., Walsh K. M., Hoeschele J. D., Pegg D. G. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam. Appl. Toxicol. 2:1994;73-79.
11. Aggarwal S. K. A histochemical approach to the mechanism of action of cisplatin and its analogues. J. Histochem. Cytochem. 41:1993;1053-1073.
12. Aggarwal S. K., Niroomand-Rad I. Effect of cisplatin on the plasma membrane phosphatase activities in ascites sarcoma-180 cells: A cytochemical study. J. Histochem. Cytochem. 31:1983;307-317.
13. Aggarwal S. K., Broomhead J. A., Fairlie D. P., Whithouse M. W. Platinum drugs: Combined anti-lymphoproliferative and nephrotoxicity assays in rats. Cancer Chemother. Pharmacol. 4:1980;249-258.
14. Sodhi A., Aggarwal S. K. Effects of cis-dichlorodiamine platinum (II) in the regression of sarcoma 180: A fine structural study. J. Natl. Cancer Inst. 53:1974;85-101.
15. Speer, R. J, Stewart, D. P. 1988, Antineoplastic platinum complexes. Patent No. 4, 739, 087.